[Federal Register Volume 62, Number 135 (Tuesday, July 15, 1997)]
[Notices]
[Pages 37946-37947]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-18516]


-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[File No. 1-12748]


Issuer Delisting; Notice of Application To Withdraw From Listing 
and Registration (Chesapeake Biological Laboratories, Inc., Class A 
Common Stock, $.01 Par Value)

July 9, 1997.
    Chesapeake Biological Laboratories, Inc. (``Company'') has filed an 
application with the Securities and Exchange Commission 
(``Commission''), pursuant to Section 12(d) of the Securities Exchange 
Act of 1934 (``Act'') and Rule 12d2-2(d) promulgated thereunder, to 
withdraw the above specified security (``Security'') from listing and 
registration on the Emerging Company Marketplace of the American Stock 
Exchange, Inc. (``Amex'').
    The reasons cited in the application for withdrawing the Security 
from listing and registration include the following:
    According to the Company, the Board of Directors unanimously 
approved a resolution on April 23, 1997 to withdraw the Company's 
Security from listing on the Emerging Company Marketplace of the Amex 
in order to move to the Nasdaq Stock Market National Market. The 
Company desires to delist its Security as it could not justify the 
increased expenses and administrative requirements associated with a 
dual listing. The Security was listed on Nasdaq effective May 27, 1997.
    The Company has complied with the Rules of the Amex by notifying 
the Amex of its intention to withdraw its Common Stock from listing on 
the

[[Page 37947]]

Exchange by letter dated May 1, 1997. The Amex has notified the 
Company, by letter dated May 1, 1997, that it would not interpose any 
objection to the Company's appreciation to delist its Security.
    Any interested person may, on or before July 30, 1997, submit by 
letter to the Secretary of the Securities and Exchange Commission, 450 
Fifth Street, N.W., Washington, D.C. 20549, facts bearing upon whether 
the application has been made in accordance with the rules of the 
exchange and what terms, if any, should be imposed by the Commission 
for the protection of investors. The Commission, based on the 
information submitted to it, will issue an order granting the 
application after the date mentioned above, unless the Commission 
determines to order a hearing on the matter.

    For the Commission, by the Division of Market Regulation, 
pursuant to delegated authority.
Jonathan G. Katz,
Secretary.
[FR Doc. 97-18516 Filed 7-14-97; 8:45 am]
BILLING CODE 8010-16-M